Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;154(1):134-40.
doi: 10.1111/j.1365-2141.2011.08698.x. Epub 2011 May 4.

Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure

Affiliations

Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure

Patrick T McGann et al. Br J Haematol. 2011 Jul.

Abstract

Hydroxycarbamide (hydroxyurea) provides laboratory and clinical benefits for adults and children with sickle cell anaemia (SCA). Given its mechanism of action and prior reports of genotoxicity, concern exists regarding long-term toxicities and possible carcinogenicity. We performed cross-sectional analyses of chromosome stability using peripheral blood mononuclear cells (PBMC) from 51 children with SCA and 3-12 years of hydroxycarbamide exposure (mean age 13·2 ± 4·1 years), compared to 28 children before treatment (9·4 ± 4·7 years). Chromosome damage was less for children receiving hydroxycarbamide than untreated patients (0·8 ± 1·2 vs. 1·9 ± 1·5 breaks per 100 cells, P = 0·004). There were no differences in repairing chromosome breaks after in vitro radiation; PBMC from children taking hydroxycarbamide had equivalent 2 Gy-induced chromosome breaks compared to untreated patients (30·8 ± 16·1 vs. 31·7 ± 8·9 per 100 cells, P = not significant). Radiation plus hydroxycarbamide resulted in similar numbers of unrepaired breaks in cells from children on hydroxycarbamide compared to untreated patients (95·8 ± 44·2 vs. 76·1 ± 23·1 per 100 cells, P = 0·08), but no differences were noted with longer exposure (97·9 ± 42·8 breaks per 100 cells for 3-6 years of hydroxycarbamide exposure vs. 91·2 ± 48·4 for 9-12 years of exposure). These observations provide important safety data regarding long-term risks of hydroxycarbamide exposure for children with SCA, and suggest low in vivo mutagenicity and carcinogenicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chromosome Abnormalities Peripheral blood mononuclear cells were isolated from venous blood samples as described in Methods. After phytohaemagglutinin stimulation, DNA damage was induced by 2Gy radiation therapy and DNA repair was inhibited by incubation with 100μM hydroxycarbamide. After lymphocytes were harvested and stained, 100 metaphase cells were examined for evidence of DNA damage, including chromatid breaks (A), chromosome breaks (B), and chromosome fusion events (C).
Figure 2
Figure 2
Effect of hydroxycarbamide exposure on chromosomal integrity For each vertical data group, the black bar represents “Flask A,” reflecting uninduced chromosome abnormalities; the grey bar represents “Flask B,” reflecting induced damage with 2Gy irradiation; the white bar represents “Flask C” reflecting induced damage and direct repair inhibition after treatment with 100μM hydroxycarbamide and 2Gy irradiation. Standard error of the mean is represented above each data point. y-axis = number of events per 100 cells; x-axis = hydroxycarbamide exposure in years. Control, n= 11 subjects; no prior hydroxycarbamide exposure, n=28; 3 years hydroxycarbamide exposure, n=15; 6 years hydroxycarbamide exposure, n=21; 9 years hydroxycarbamide exposure, n=4; 12 years hydroxycarbamide exposure, n=11.

References

    1. Ariel IM. Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors. Cancer. 1970;25:705–714. - PubMed
    1. Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, James AH, Laraque D, Mendez M, Montoya CJ, Pollock BH, Robinson L, Scholnik AP, Schori M. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148:932–938. - PubMed
    1. Brenner DJ, Hall EJ. Computed Tomography – An Increasing Source of Radiation Exposure. N Engl J Med. 2007;357:2277–2284. - PubMed
    1. Cassileth PA, Hyman GA. Treatment of malignant melanoma with hydroxyurea. Cancer Res. 1967;27:1843–1845. - PubMed
    1. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G, Jr., Platt OS. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79:2555–2565. - PubMed

Publication types